H2O2 promotes photodynamic efficacy of TMPyP4 against ovarian cancer in vitro by downregulating HIF-1α expression - 23/07/24
Abstract |
Photodynamic therapy (PDT), employing photosensitizers to induce formation of reactive oxygen species (ROS) for tumor elimination, is emerging as a promising treatment modality in oncology due to its unique benefits. However, the PDT application in ovarian cancer, the most prevalent and lethal type of gynecological malignancy with a severe hypoxic microenvironment, remains unknown. This study revealed that photosensitizer TMPyP4 exhibited enhanced efficacy under H2O2 stimulation, with minimal change in cytotoxicity compared to TMPyP4 alone. The results showed that H2O2 increased ROS production induced by TMPyP4, leading to exacerbated mitochondrial dysfunction and DNA damage, ultimately inhibiting proliferation and inducing apoptosis in ovarian cancer cells. Mechanistically, H2O2 primarily enhanced the therapeutic efficacy of PDT with TMPyP4 against ovarian cancer cells by degrading HIF-1α, which subsequently modulated the HIF-1 signaling pathway, thereby alleviating the hypoxic environment in ovarian cancer cells. Our findings underscore the therapeutic potential of targeting HIF-1α within the hypoxic microenvironment for PDT in ovarian cancer and propose a novel integrated strategy for PDT treatment of this malignancy in vitro.
Le texte complet de cet article est disponible en PDF.Highlights |
• | H2O2 enhances the efficiency of TMPyP4-guided PDT against ovarian cancer in vitro. |
• | H2O2 promotes mitochondrial dysfunction and DNA damage in TMPyP4-treated ovarian cancer cells. |
• | H2O2 enhances TMPyP4-induced ROS production by inhibiting HIF-1α transcription and expression in vitro. |
• | HIF-1α is a potential target for PDT in ovarian cancer. |
• | TMPyP4 combined with H2O2 shows promise as a PDT strategy for ovarian cancer treatment in vitro. |
Keywords : PDT, Hypoxia, Ovarian cancer, TMPyP4, H2O2, HIF-1α
Plan
Vol 177
Article 117110- août 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?